Bio-Rad Laboratories, Inc. Announces Launch of Four New Droplet Digital?? PCR (ddPCR??) Platforms

Published: 2025-07-07 09:50:22 ET BIO

Published on 07/07/2025 at 09:50

Bio-Rad Laboratories, Inc. announced the launch of four new Droplet Digital?? PCR (ddPCR??) platforms. The newly introduced instruments include Bio-Rad's QX Continuum?? ddPCR system along with the QX700??

series of ddPCR platforms acquired as part of the company's recently completed acquisition of digital PCR developer Stilla Technologies. Together with Bio-Rad's existing line of QX200?? and QX600??

ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR products for life science research and diagnostic applications. The end-to-end solutions feature absolute quantification, high precision, and advanced multiplexing capabilities, combined with streamlined and simplified workflows. The QX Continuum??dPCR system is designed for translational research applications.

It features qPCR-like workflow offering simplicity, performance and flexibility in an all-in-one configuration with four-color multiplexing and up to eight discrete thermal profiles per plate. The QX700?? series consistsof three new ddPCR instruments designed for academic research, environmental testing, cell and gene therapy, and biopharma quality control workflows.

The systems enable seven-color multiplexing, capacity to process over 700 samples per day, with minimal input volume, continuous loading capability, and easy-to-use software for streamlined data interpretation.